Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

A new partnership between the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and ARcare aims to improve colorectal cancer screening rates in seven rural Arkansas counties where late-stage diagnoses and cancer disparities are on the rise.

July 25, 2025

Vol.51 No.29

Clinical Roundup

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Reduced screening rates and a higher prevalence of triple-negative breast cancer are driving elevated rates of advanced breast cancer in a geographic hotspot in Wilmington, Delaware, according to findings by researchers at ChristianaCare’s Cawley Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute.

July 25, 2025

Vol.51 No.29

Drugs & Targets

Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer

Chinese authorities granted the marketing authorization for Braftovi (encorafenib) in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.

July 18, 2025

Vol.51 No.28

Drugs & Targets

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Personalis Inc. and Tempus AI Inc. have expanded and extended their strategic collaboration, adding a new indication, colorectal cancer, to the existing, exclusive commercialization agreement.

July 11, 2025

Vol.51 No.27

In Brief

Justin Taylor named recipient of Stanley J. Glaser Award to reseach potential colorectal cancer treatment

Justin Taylor, a physician-scientist at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has received a Stanley J. Glaser Foundation Research Award to continue the research.

June 20, 2025

Vol.51 No.24

Clinical Roundup

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

First-line treatment with the triplet combination of encorafenib, cetuximab, and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic colorectal cancer, according to new data from the phase III BREAKWATER trial led by researchers from the University of Texas MD Anderson Cancer Center.

June 06, 2025

Vol.51 No.22

Mainz Biomed and Thermo Fisher collaborate to develop next-gen global CRC screening product

YOU MAY BE INTERESTED IN

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

ChristianaCare research reveals drivers behind advanced breast cancer in hotspots

Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Justin Taylor named recipient of Stanley J. Glaser Award to reseach potential colorectal cancer treatment

MD Anderson study: Triple therapy regimen significantly improves survival in BRAF V600E-mutated metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login